Fundraising FoxSolve Therapeutics
Belmont, US · Founded 2021 · 5 known investors
Find your way into Solve Therapeutics
Sign up to find every way you can get introduced to Solve Therapeutics
- Your email: who you already know at Solve Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Solve Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection. The company has two lead programs in Phase 1 clinical development.
Founders & leadership
DJ
David JohnsonChief Executive Officer
CK
Clayton KnoxPresident
KJ
Katti JessenSVP, Translational Sciences
YK
Yakov KoganHead of Operations
BL
Brian LannuttiResearch & Development Leadership
LM
Langdon MillerClinical Development Leadership
JS
Jeff SchaalRadiopharmaceutical Discovery & Development Lead
MS
Mike SunCMC Leadership
JW
Jeff WatkinsProtein Engineering Leadership
JW
Jon WilliamsSVP of Finance
Board
PC
Peter ColabuonoBoard director
AC
Alan ColowickBoard director
Investors · 5
Decheng Capital✓ confirmed by Solve TherapeuticsMenlo Park
How we know: the company's own site · Decheng Capital's portfolio page · Not right? Tell us
Matrix Capital Management✓ confirmed by Solve TherapeuticsPortsmouth
How we know: the company's own site · Not right? Tell us
Yosemite✓ confirmed by Solve TherapeuticsSan Francisco
How we know: the company's own site · Not right? Tell us
.jpeg){kind=logo}
Reported raises · per SEC filings
Form D private placements$162.1M disclosed across 3 rounds · 2021–2025
▶$48.2MraisedNov 2025 · 16 investors · BiotechnologyRule 506(b)
▶$48.2MraisedNov 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel McHughDirector
- Langdon MillerExecutive Officer
- David JohnsonExecutive Officer, Director
- Clayton D. KnoxExecutive Officer
- Robert MittendorffDirector
- Alan ColowickDirector
- Jason PittsDirector
- Peter ColabuonoDirector
- Offering amount
- $120.5M
- Amount sold
- $48.2M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$50.4MraisedDec 2024 · 10 investors · BiotechnologyRule 506(b)
▶$50.4MraisedDec 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter ColabuonoDirector
- Langdon MillerExecutive Officer
- Alan ColowickDirector
- David JohnsonExecutive Officer, Director
- Clayton D. KnoxExecutive Officer
- Jason PittsDirector
- Offering amount
- $75.6M
- Amount sold
- $50.4M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$63.5MraisedJan 2022 · 11 investors · BiotechnologyRule 506(b)
▶$63.5MraisedJan 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter ColabuonoDirector
- Langdon MillerExecutive Officer
- Alan ColowickDirector
- David JohnsonExecutive Officer, Director
- Offering amount
- $126.5M
- Amount sold
- $63.5M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
SoluSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Companies working in the same space as Solve Therapeutics.
Frequently asked questions
- What does Solve Therapeutics do?
- Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection. The company has two lead programs in Phase 1 clinical development.
- Who are Solve Therapeutics's investors?
- Solve Therapeutics's investors include Decheng Capital, Matrix Capital Management, Yosemite, B Capital Group, B4 Capital.
- How much funding has Solve Therapeutics raised?
- Solve Therapeutics has disclosed $162.1M raised across 3 rounds.
- Where is Solve Therapeutics headquartered?
- Solve Therapeutics is headquartered in Belmont, US.